StockData

Innate Pharma vs TScan Therapeutics

IPHA and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IPHA and TCRX compare

TScan Therapeutics grew revenue faster over the last twelve months (2.2% versus −55.2% for Innate Pharma).

TScan Therapeutics scores higher on the StockData Score (4 against 0 for Innate Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIPHATCRX
Size and price
Market cap–$10.2M
Share price$1.33$0.151
Change, 1 year−26.9%−86.3%
Change, 5 years−72.3%−98.3%
Beta (5Y)1.282.15
Employees181142
StockData Score
Total score04 (better)
Valuation score03 (better)
Growth score00
Performance score00
Health score01 (better)
Dividend score00
Valuation
P/S–1.4×
P/B–0.1×
FCF yield–−1157%
Fair value–$1.36
Margin of safety–88.9%
Growth
Revenue growth (TTM)−55.2%2.2% (better)
Revenue growth, 5Y average−33.6%56.9% (better)
Profitability
Operating margin−600% (better)−1695%
Net margin–−1655%
FCF margin−587% (better)−1666%
Return on equity–−95.8%
Financial health
Debt / equity–0.47
Interest coverage−17.3× (better)−43.2×
Current ratio0.603.37 (better)
Altman Z-score–−6.31
Piotroski F-score–2
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions0.21%53.5%
Held by insiders16.2%32.8%
Insider net buying, 12 months–$146K
Short interest, % of float–4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.